Our Science: IGX12
FIRST POTENTIAL mAb TREATMENT FOR INFERTILITY
Igyxos’ initial clinical candidate is IGX12, a first-in-class humanized monoclonal antibody (mAb). Evaluated in validated pre-clinical models, IGX12 is supported by a foundation of compelling data. IGX12 has been shown to:
​
• Increase FSH potency and efficacy in cellular signaling
• Enhance FSH potency on ovarian stimulation across several in vivo female animal models
• Boost spermatogenesis in male rat and murine models
With its unique MOA for increasing FSH potency and efficacy, IGX12 has potential to be a transformational therapy in the treatment of infertility.
TARGETING UNMET FERTILITY SOLUTION NEEDS IN MEN AND WOMEN
Initial infertility treatment indications for IGX12 are oligozoospermic men and in vitro fertilization (IVF) in women.
​
By boosting the efficacy and potency of FSH, IGX12 has broad potential to significantly improve spermatogenesis in men with oligozoospermia where, as of now, no treatment is approved. IGX12 would then offer a new path in men infertility treatment whereas today, the only possibility is to treat women even if the cause of infertility comes from men.
​
IGX12 can also optimize IVF treatment outcomes by improving oocyte maturation, while reducing FSH injections. The treatment burden of IVF requires multiple FSH injections with only 40 to 50 % of couples having a baby after an average of 4 to 5 treatment cycles. ​
CLINICAL STUDIES UNDERWAY
We have successfully conducted a Single Ascending Dose study in both female and male volonteers. The Multiple Ascending Dose study in male volunteers is currently ongoing.
We have partnered with global industry leaders for the generation of IGX12 clinical material. Our key partners include Merck Biodevelopment/EMD Millipore and Baccinex for chemistry, manufacturing, and controls (CMC) development, ERBC from preclinical studies and CRS (Berlin) for clinical studies.